PRL and breast carcinoma: Treatment with selective serotonin reuptake inhibitors (SSRIs) may increase circulating prolactin levels [39, 40], which could potentially increase the risk of breast cancer by stimulating cellular proliferation, differentiation, and angiogenesis [13].